Details for New Drug Application (NDA): 208423
✉ Email this page to a colleague
NDA 208423 describes LINAGLIPTIN, which is a drug marketed by Invagen Pharms, Sunshine, and Zydus Pharms, and is included in five NDAs. Additional details are available on the LINAGLIPTIN profile page.
The generic ingredient in LINAGLIPTIN is linagliptin; metformin hydrochloride. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the linagliptin; metformin hydrochloride profile page.
The generic ingredient in LINAGLIPTIN is linagliptin; metformin hydrochloride. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the linagliptin; metformin hydrochloride profile page.
Summary for 208423
| Tradename: | LINAGLIPTIN |
| Applicant: | Invagen Pharms |
| Ingredient: | linagliptin |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 208423
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 5MG | ||||
| Approval Date: | Sep 3, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
